FibroGen
Dr. Olga V. Gambetti, MD, PhD, DrMedSci is an experienced medical professional with a robust background in clinical development and endocrinology. Currently serving as Medical Director of Clinical Development at FibroGen, Inc. since February 2022, Dr. Gambetti previously held the position of Medical Director at Ascendis Pharma A/S from December 2016 to August 2021, and at Ipsen BioPharmaceuticals from January 2015 to December 2016. Earlier roles include Clinical Research Consultant at BioMarin Pharmaceutical Inc. and Clinical Registry Liaison at Ipsen, alongside significant experience as Research Associate at Oregon Health & Science University and as Director of the Growth Center at the Endocrinology Research Center.
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.